Advanced search
Publication Cover
Nanomedicine Volume 9, 2014 - Issue 11
Submit an article Journal homepage
205
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Liposomal Codelivery of A Synergistic Combination of Bioactive Lipids in The Treatment of Acute Myeloid Leukemia

Kuan-Boone Tan1 Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4, 02–09, 18 Science Drive 4, Singapore117543, SingaporeView further author information
,
Leong-Uung Ling1 Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4, 02–09, 18 Science Drive 4, Singapore117543, SingaporeView further author information
,
Ralph M Bunte2 Office of Research, Duke-National University of Singapore Graduate Medical School, SingaporeView further author information
,
Wee-Joo Chng3 Cancer Science Institute of Singapore, National University of Singapore, Singapore;4 Department of Haematology-Oncology, National University Cancer Institute of Singapore, National University Health System, Singapore;5 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, SingaporeView further author information
&
Gigi NC Chiu1 Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4, 02–09, 18 Science Drive 4, Singapore117543, SingaporeCorrespondence[email protected]
View further author information
Pages 1665-1679 | Received 27 Feb 2013, Accepted 25 Jun 2013, Published online: 16 Oct 2014

References

  • Roboz GJ . Novel approaches to the treatment of acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ. Program2011(1), 43–50 (2011).
  • Bow EJ , SutherlandJA, KilpatrickMGet al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J. Clin. Oncol. 14(4), 1345–1352 (1996).
  • Milligan DW , WheatleyK, LittlewoodT, CraigJIO, Burnett AK; NCRI Haematological Oncology Clinical Studies Group. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood107(12), 4614–4622 (2006).
  • Virchis A , KohM, RankinPet al. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br. J. Haematol. 124(1), 26–32 (2004).
  • Feldman EJ , SeiterK, DamonLet al. A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia 11(4), 485–489 (1997).
  • Hasle H , AbrahamssonJ, ForestierEet al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood 120(5), 978–984 (2012).
  • Fröhling S , SchollC, GillilandDG, LevineRL. Genetics of myeloid malignancies: pathogenetic and clinical implications. J. Clin. Oncol.23(26), 6285–6295 (2005).
  • Alkan S , HuangQ, ErginMet al. Survival role of protein kinase C (PKC) in chronic lymphocytic leukemia and determination of isoform expression pattern and genes altered by PKC inhibition. Am. J. Hematol. 79(2), 97–106 (2005).
  • Cuvillier O , LevadeT. Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood98(9), 2828–2836 (2001).
  • Amin HM , ErginM, DenningMF, QuevedoME, AlkanS. Characterization of apoptosis induced by protein kinase C inhibitors and its modulation by the caspase pathway in acute promyelocytic leukaemia. Br. J. Haematol.110(3), 552–562 (2000).
  • Dickson MA , CarvajalRD, MerrillAH Jr, Gonen M, Cane LM, Schwartz GK. A Phase I clinical trial of safingol in combination with cisplatin in advanced solid tumors. Clin. Cancer Res.17(8), 2484–2492 (2011).
  • Jatoi A , SumanVJ, SchaeferPet al. A Phase II study of topical ceramides for cutaneous breast cancer. Breast Cancer Res. Treat. 80(1), 99–104 (2003).
  • Shabbits JA , MayerLD. Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro.Biochim. Biophys. Acta1612(1), 98–106 (2003).
  • Shikata K , NiiroH, AzumaH, OginoK, TachibanaT. Apoptotic activities of C2-ceramide and C2-dihydroceramide homologues against HL-60 cells. Bioorg. Med. Chem.11(13), 2723–2728 (2003).
  • Demarchi F , BertoliC, GreerPA, SchneiderC. Ceramide triggers an NF-kappa B-dependent survival pathway through calpain. Cell Death Differ.12(5), 512–522 (2005).
  • Iwayama H , UedaN. Role of mitochondrial Bax, caspases, and MAPKs for ceramide-induced apoptosis in renal proximal tubular cells. Mol. Cell. Biochem.379(1–2), 37–42 (2013).
  • Taniguchi M , KitataniK, KondoTet al. Regulation of autophagy and its associated cell death by ‘sphingolipid rheostat‘: reciprocal role of ceramide and sphingosine 1-phosphate in the mammalian target of rapamycin pathway. J. Biol. Chem. 287(47), 39898–39910 (2012).
  • Siskind LJ , ColombiniM. The lipids C2- and C16-ceramide form large stable channels. Implications for apoptosis. J. Biol. Chem.275(49), 38640–38644 (2000).
  • Richter C , GhafourifarP. Ceramide induces cytochrome c release from isolated mitochondria. Biochem. Soc. Symp.66, 27–31 (1999).
  • Buehrer BM , BellRM. Inhibition of sphingosine kinase in vitro and in platelets. Implications for signal transduction pathways. J. Biol. Chem.267(5), 3154–3159 (1992).
  • Buehrer BM , BellRM. Sphingosine kinase: properties and cellular functions. Adv. Lipid Res.26, 59–67 (1993).
  • Paugh SW , PaughBS, RahmaniMet al. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood 112(4), 1382–1391 (2008).
  • Mayer LD , HarasymTO, TardiPGet al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 5(7), 1854–1863 (2006).
  • Feldman EJ , KolitzJE, TrangJMet al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk. Res. 36(10), 1283–1289 (2012).
  • Perkins WR , DauseRB, LiXet al. Combination of antitumor ether lipid with lipids of complementary molecular shape reduces its hemolytic activity. Biochim. Biophys. Acta 1327(1), 61–68 (1997).
  • Lee S , KimJ, ShimGet al. Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor. J. Control. Release 164(2), 213–220 (2012).
  • Zhukova MV , RomanenkoOV, NikolaevichVA, KiselMA. Hemolytic properties of miltefosine in liposomes of various lipid compositions. Pharm. Chem. J.44(9), 507–509 (2010).
  • Tan K-B , Ling L-U, Bunte RM, Chng W-J, Chiu GNC. In vivo efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia. J. Control. Release160(2), 290–298 (2012).
  • Feldman EJ , LancetJE, KolitzJEet al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J. Clin. Oncol. 29(8), 979–985 (2011).
  • Allen TM , CullisPR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev.65(1), 36–48 (2013).
  • Ling LU , TanKB, LinH, ChiuGNC. The role of reactive oxygen species and autophagy in safingol-induced cell death. Cell Death Dis.2, e129 (2011).
  • Ling LU , TanKB, ChiuGNC. Role of reactive oxygen species in the synergistic cytotoxicity of safingol-based combination regimens with conventional chemotherapeutics. Oncol. Lett.2(5), 905–910 (2011).
  • Fiske CH , SubbarowY. The colorimetric determination of phosphorus. J. Biol. Chem.66(2), 375–400 (1925).
  • Kedderis LB , BozigianHP, KleemanJMet al. Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. Fundam. Appl. Toxicol. 25(2), 201–217 (1995).
  • Cullis PR , KruijffBD. Lipid polymorphism and the functional roles of lipids in biological membranes. Biochim. Biophys. Acta559(4), 399–420 (1979).
  • Johnsson M , EdwardsK. Liposomes, disks, and spherical micelles: aggregate structure in mixtures of gel phase phosphatidylcholines and poly(ethylene glycol)-phospholipids. Biophys. J.85(6), 3839–3847 (2003).
  • Chou TC . The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Synergism and Antagonism in Chemotherapy. Chou TC, Rideout DC (Eds). Academic Press, CA, USA (1991).
  • Hannun YA , ObeidLM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol.9(2), 139–150 (2008).
  • Perkins WR , DauseRB, LiXet al. Combination of antitumor ether lipid with lipids of complementary molecular shape reduces its hemolytic activity. Biochim. Biophys. Acta 1327(1), 61–68 (1997).
  • Watters RJ , KesterM, TranMA, Loughran Jr TP, Liu X. Development and use of ceramide nanoliposomes in cancer. In: Methods in Enzymology. Nejat D (Ed.). Academic Press, CA, USA, 89–108 (2012).
  • Appelbaum FR , RosenblumD, ArceciRJet al. End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 109(5), 1810–1816 (2007).
  • Vardiman JW . The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms. Chem. Biol. Interact.184(1–2), 16–20 (2010).
  • Torrecillas A , Aroca-AguilarJD, ArandaFJet al. Effects of the anti-neoplastic agent ET-18-OCH3 and some analogs on the biophysical properties of model membranes. Int. J. Pharm. 318 (1–2), 28–40 (2006).
  • Koshkaryev A , PiroyanA, TorchilinVP. Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes. Cancer Biol. Ther.13(1), 50–60 (2012).
  • Chiu GN , BallyMB, MayerLD. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim. Biophys. Acta1510(1–2), 56–69 (2001).
  • Chou TC . Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res.70(2), 440–446 (2010).
  • Chiu GN , WongMY, LingLUet al. Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: implications on pharmacokinetics and drug toxicities. Curr. Drug Metab. 10(8), 861–874 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.